Source comparison
TB-500 vs BPC-157 vs Standard Recovery Protocols
Primary Mechanism Actin polymerization, angiogenesis, anti-fibrotic Nitric oxide pathway, GI mucosal protection, systemic repair COX enzyme inhibition, inflammation suppression Growth factor delivery, platelet-derived healing cascade TB-500 and BPC-157 address
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Actin polymerization, angiogenesis, anti-fibrotic
- Nitric oxide pathway, GI mucosal protection, systemic repair
- COX enzyme inhibition, inflammation suppression
- Growth factor delivery, platelet-derived healing cascade
- TB-500 and BPC-157 address different injury phases. TB-500 excels in proliferative/remodeling, BPC-157 in acute inflammation
- Effective Injury Types
- Tendinopathy, ligament strain, muscle tears
- GI damage, tendon inflammation, joint injuries
- Acute inflammatory pain only
- Tendon/ligament degeneration with poor vascularity
- TB-500 for chronic overuse; BPC-157 for acute flare-ups; PRP for structural tears
- Dosing Frequency
- 2–3× per week during loading phase
- Daily (200–500mcg subcutaneous or oral)
- As-needed or scheduled (contraindicated >10 days)
- Single injection, possibly repeated at 6–12 weeks
- TB-500 requires commitment to multi-week protocol; BPC-157 more flexible
- Evidence Base
- Veterinary equine studies, limited human RCTs
- Rodent models, case reports, no Phase III human trials
- Extensive human data but healing delays documented
- Mixed results; effective in ~60% of cases per orthopedic literature
- Strongest evidence: TB-500 in animal tendon repair; weakest: BPC-157 human trials
- Cost (4-week protocol)
- $120–$200 for 20mg total
- $80–$150 for 8.4mg total
- $15–$30 OTC
- $500–$1500 per injection
- TB-500 and BPC-157 comparable; PRP 5–10× more expensive per treatment
- Scar Tissue Prevention
- Documented in tendon studies (reduces type III collagen)
- Limited data; claims exceed evidence
- Worsens fibrosis by delaying healing
- No direct anti-fibrotic effect
- TB-500 is the only option with published anti-fibrotic mechanism